MiR-10b表达与早期乳腺浸润性导管癌分子亚型相关性分析

发布时间：2018-03-13 12:43

本文选题：早期乳腺浸润性导管癌　切入点：miR-10b　出处：《新疆医科大学》2017年硕士论文　论文类型：学位论文

【摘要】：目的:探讨miR-10b表达与乳腺早期浸润性导管癌分子亚型两者相关性。方法:针对305例乳腺早期浸润性导管癌中的miR-10b的表达使用原位分子杂交技术进行检测,乳腺早期浸润性导管癌中雌激素受体(ER-α)、孕激素受体(PR)、人类表皮生长因子受体-2(Her-2)表达给予免疫组化检测,根据ER-α、PR及Her-2分为四个分子亚型。分析不同临床指标间miR-10b表达的差异性使用Pearson卡方检验方法;Spearman秩合检验方法分析早期乳腺浸润性导管癌中miR-10b、分子亚型、ER-α、PR、Her-2和淋巴结状态相互关联性。计算累计无瘤生存时间用Kaplan-Meier法;分析中位无瘤生存时间使用Log-rank检验进行。结果:miR-10b表达与患者年龄、ER-α、PR及复发转移,差异具有统计学意义(P0.05);与月经状态、肿瘤大小、临床分期及总淋巴、化疗以及放疗、内分泌治疗,差异无统计学意义(P0.05)。早期乳腺浸润性导管癌中mi R-10b表达与不同分子亚型中具有显著性差异(P0.05),miR-10b与分子亚型呈正相关,miR-10b阳性表达中Basal-like型所占比例明显高于其它三种分子亚型。mi R-10b阳性表达无瘤生存率显著下降,预后差。早期乳腺浸润性导管癌四种分子亚型中,Luminal B型差异具有统计学意义(P0.05);Luminal A型、Her-2过表达型、Basal-like型经Log-rank检验,差异不具有统计学意义(P0.05)。结论:miR-10b在乳腺早期浸润性导管癌中的阳性表达与ER-α、年龄及复发转移具有一定的相关性,且mi R-10b阳性表达是其分子亚型的预后不良指标,miR-10b表达对其预后判断提供帮助。
[Abstract]:Objective: to investigate the relationship between the expression of miR-10b and molecular subtypes of early invasive ductal carcinoma of breast. Methods: the expression of miR-10b in 305 cases of early invasive ductal carcinoma of breast was detected by in situ molecular hybridization. The expression of estrogen receptor ER- 伪, progesterone receptor, human epidermal growth factor receptor-2 and human epidermal growth factor receptor-2 Her-2 in early invasive ductal carcinoma of the breast were detected by immunohistochemistry. According to ER- 伪 -PR and Her-2, there are four molecular subtypes. To analyze the difference of miR-10b expression among different clinical indexes, Pearson chi-square test was used to analyze miR-10b, molecular subtype ER- 伪 -PRN Her-2 and lymphadenoid ductal carcinoma in early stage of breast invasive ductal carcinoma by using Spearman rank test. The cumulative tumor-free survival time was calculated by Kaplan-Meier method. Log-rank test was used to analyze the median tumor-free survival time. Results the expression of micromiR-10b was significantly different from age, ER- 伪 PR, recurrence and metastasis, and with menstrual status, tumor size, clinical stage, total lymph node, chemotherapy and radiotherapy. Endocrine therapy, The expression of miR-10b in early invasive ductal carcinoma of breast was significantly different from that in different molecular subtypes. There was a positive correlation between the expression of miR-10b and the molecular subtypes. The proportion of Basal-like type in the positive expression of P0.05 and molecular subtypes was significantly higher than that of the other three subtypes. The tumor-free survival rate of subtype .mi R-10b was significantly decreased. The prognosis was poor. Among the four molecular subtypes of early invasive ductal carcinoma of breast, the difference of Luminal B was statistically significant. Conclusion the positive expression of 1% miR-10b in early invasive ductal carcinoma of the breast is correlated with ER- 伪, age, recurrence and metastasis. The positive expression of miR-10b was a poor prognostic marker of its molecular subtype, and the expression of miR-10b was helpful to its prognosis.
【学位授予单位】：新疆医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.9

【相似文献】